Combating Rising Antimicrobial Resistance: Advancing Public Health Preparedness, Antibiotics, & Innovation

Duke-Margolis Center for Health Policy

Webinar Agenda | May 12, 2021 | 11:00 am - 12:30 pm ET

11:00 am Welcome and Opening Remarks
Mark McClellan, Director, Duke-Margolis Center for Health Policy
Scott Gottlieb, Resident Fellow, American Enterprise Institute

11:10 am A Conversation With Senator Michael Bennet: Investing in Preparedness to Sustain Innovation and Protect Public Health
Mark McClellan moderates a conversation with Senator Michael Bennet that will explore increasing attention toward AMR and why U.S. investments in public health preparedness and innovation are both timely and critically important.

11:25 am Session 2: Global Policy Leadership and Proposals to Combat AMR
This session will highlight how the U.S. can lead policy approaches to combat AMR through existing legislative proposals and opportunities to coordinate domestic actions with existing international efforts. Panelists will explore how to:

- Maintain political momentum toward substantial domestic pull-incentives for novel antibiotics, including the proposed PASTEUR and SUPERBUGS Acts;
- Leverage G7 and G20 leadership opportunities;
- Coordinate domestic and international actions to combat AMR; and
- Engage policymakers, legislators, and private-sector partners to advance immediate next steps.

Panel Discussion
- Candace Dematteis, Partnership to Fight Infectious Disease (PFID)
- Lynn Filpi, Office of Global Affairs, Office of the Secretary, HHS
- Silas Holland, AMR Action Fund
- Kevin Outterson, CARB-X & Boston University

11:55 am Session 3: Innovations to Combat AMR and Emerging Infectious Diseases
This session will focus on how to prepare for future pandemics and public health threats, as well as lessons learned from the coronavirus pandemic that might be applied to prevent or respond to rising AMR and threatening emerging infectious diseases. Panelists will explore how to:

- Prepare U.S. government agencies, drug and vaccine developers, manufacturers, and supply chain partners for future threats;
• Support flexible and affordable U.S. manufacturing and supply chain infrastructure;
• Support enhanced domestic and global threat surveillance; and
• Maintain ongoing support for rapid diagnostic capacity and innovation.

Panel Discussion
• Jason Burdette, Paratek Pharmaceuticals
• Allan Coukell, CivicaRx
• Michael Craig, Centers for Disease Control & Prevention
• John H. Rex, F2G Ltd. & Advent Life Sciences

12:25 pm  Closing Remarks
Mark McClellan, Director, Duke-Margolis Center for Health Policy

12:30 pm  Adjournment